title: Ciprofibrate treatment decreases non-high density lipoprotein cholesterol and triglycerides and increases high density lipoprotein cholesterol in patients with Frederickson type IV dyslipidemia phenotype.
abstract: OBJECTIVE
  The combination of hypertriglyceridemia and low high density lipoprotein (HDL) cholesterol is one of the most common lipid abnormalities. Thus, the aim of this study was to determine the effects of ciprofibrate on lipid profile in patients with Frederickson's type IV dyslipidemia phenotype.
  
  
  METHODS
  Seventy-five patients with type IV dyslipidemia were assigned at random to 1 of 2 therapeutic options: group A (control), American Heart Association (AHA) Step II diet and physical activity; and group B, AHA diet, physical activity, and ciprofibrate 100 mg daily for 8 weeks. The lipid profile of all patients was determined at baseline and after therapeutic intervention.
  
  
  RESULTS
  Patients in group B (treated with ciprofibrate) compared with group A (control) had significantly higher reductions in total cholesterol (downward arrow 14.2% vs. downward arrow 4.8%; P < 0.02), triglycerides (downward arrow 38.0% vs. downward arrow 21.6%; P < 0.007), very low density lipoprotein cholesterol (downward arrow 38.0% vs. downward arrow 21.6%; P < 0.007), non-HDL cholesterol (downward arrow 20.5% vs. downward arrow 7.1%; P < 0.007), and total cholesterol/high density cholesterol ratio (downward arrow 25.6% vs. downward arrow 9.4%; P < 0.01). The ciprofibrate group had a significantly higher increase in HDL cholesterol levels compared with the other group (upward arrow 25.0% vs. upward arrow 9.6%, P < 0.02).
  
  
  CONCLUSIONS
  Ciprofibrate treatment effectively reduced triglyceride-rich particles and non-HDL cholesterol, and significantly increased HDL cholesterol, proving its effectiveness in patients with low HDL cholesterol and type IV Frederickson's hyperlipidemia.
authors.affiliation: Endocrine and Metabolic Diseases Research Center Dr. Félix Gómez, University of Zulia, School of Medicine, Maracaibo, Venezuela. vbermudez@hotmail.com
authors.forename: Valmore
authors.initials: V
authors.lastname: Bermúdez-Pirela
authors.forename: Aida
authors.initials: A
authors.lastname: Souki
authors.forename: Clímaco
authors.initials: C
authors.lastname: Cano-Ponce
authors.forename: Fernando
authors.initials: F
authors.lastname: Bermúdez-Arias
authors.forename: Edgardo
authors.initials: E
authors.lastname: Mengual-Moreno
authors.forename: Elliuz
authors.initials: E
authors.lastname: Leal-Gonzalez
authors.forename: Miguel
authors.initials: M
authors.lastname: Lemus-Antepaz
authors.forename: Mayela Cabrera
authors.initials: MC
authors.lastname: de Bravo
authors.forename: Anilsa Amell
authors.initials: AA
authors.lastname: de Díaz
authors.forename: Nilka Leal
authors.initials: NL
authors.lastname: de Pirela
authors.forename: Raquel
authors.initials: R
authors.lastname: Cano-Peñaloza
authors.forename: Guillermo
authors.initials: G
authors.lastname: Puche-Medina
authors.forename: Navlet
authors.initials: N
authors.lastname: Arraiz
authors.forename: Nadia
authors.initials: N
authors.lastname: Reyna-Villazmil
authors.forename: Freddy
authors.initials: F
authors.lastname: Contreras
authors.forename: Zafar H
authors.initials: ZH
authors.lastname: Israili
authors.forename: Manuel
authors.initials: M
authors.lastname: Valasco
mesh_terms: D008076:Cholesterol, HDL / Q000097:blood*; D008078:Cholesterol, LDL / Q000097:blood*; D015243:Cholesterol, VLDL / Q000097:blood*; D002995:Clofibric Acid / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D058607:Fibric Acids; D006801:Humans; D006953:Hyperlipoproteinemia Type IV / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010641:Phenotype; D014280:Triglycerides / Q000097:blood*
chemical_list: D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D015243:Cholesterol, VLDL; D058607:Fibric Acids; D000960:Hypolipidemic Agents; D014280:Triglycerides; D002995:Clofibric Acid; C019304:ciprofibrate